[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6363 Introduced in House (IH)]
<DOC>
117th CONGRESS
2d Session
H. R. 6363
To direct the Comptroller General of the United States to conduct a
study on funding to entities utilizing such funding for human genomic
sequencing or genetic services.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
January 10, 2022
Mr. Bucshon introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To direct the Comptroller General of the United States to conduct a
study on funding to entities utilizing such funding for human genomic
sequencing or genetic services.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Genetic Sequencing Accountability
Act''.
SEC. 2. GAO STUDY.
(a) In General.--The Comptroller General of the United States
(referred to in this section as the ``Comptroller General'') shall
conduct a study to assess the extent to which the Department of Health
and Human Services (referred to in this section as the ``Department'')
utilizes or provides funding to entities that utilize such funds for
human genomic sequencing services or genetic services (as such term is
defined in section 201(6) of the Genetic Information Nondiscrimination
Act of 2008 (42 U.S.C. 2000ff(6))) provided by entities organized under
the laws of a country or countries of concern, in the estimation of the
Director of National Intelligence or the head of another Federal
department or agency, as appropriate.
(b) Considerations.--In carrying out the study under this section,
the Comptroller General shall--
(1) consider--
(A) what is known about the extent to which the
country or countries of concern could obtain human
genomic information of citizens and residents of the
United States from such entities that sequence,
analyze, collect, or store human genomic information
and which the Director of National Intelligence or the
head of another Federal department or agency reasonably
anticipates may use such information in a manner
inconsistent with the national security interests of
the United States;
(B) whether the Department or recipient of such
funds from the Department sought to provide funding to,
or to use, domestic entities with no such ties to the
country or countries of concern for such purposes and
any barriers to the use of domestic entities; and
(C) whether the Department has processes in place
to ensure that data use agreements, data security
measures, and other such measures taken by the
Department or recipient of such funds from the
Department are sufficient to protect the identifiable,
sensitive information of the people of the United
States and the national security interests of the
United States; and
(2) make recommendations to address any vulnerabilities to
the United States national security identified, as appropriate.
(c) Estimation.--In conducting the study under this section, the
Comptroller General may, as appropriate and necessary to complete such
study, investigate specific instances of such utilization of genetic
sequencing services or genetic services, as described in subsection
(a), to produce estimates of the potential prevalence of such
utilization among entities in receipt of Departmental funds.
(d) Report.--Not later than 2 years after the date of enactment of
this Act, the Comptroller General shall submit a report on the study
under this section to the Committee on Health, Education, Labor, and
Pensions and the Select Committee on Intelligence of the Senate, and
the Committee on Energy and Commerce and the Permanent Select Committee
on Intelligence of the House of Representatives. The report shall be
submitted in unclassified form, to the extent practicable, but may
include a classified annex.
<all>